Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-11,900
Closed -$958K 536
2022
Q3
$958K Buy
11,900
+1,900
+19% +$161K 0.03% 567
2022
Q2
$745K Sell
10,000
-22,000
-69% -$2.01M 0.03% 606
2022
Q1
$4.09M Buy
32,000
+21,200
+196% +$2.32M 0.14% 165
2021
Q4
$1.45M Sell
10,800
-5,600
-34% -$805K 0.05% 448
2021
Q3
$2.24M Sell
16,400
-18,000
-52% -$2.27M 0.07% 405
2021
Q2
$3.67M Buy
34,400
+26,400
+330% +$2.54M 0.12% 196
2021
Q1
$719K Buy
8,000
+4,400
+122% +$413K 0.02% 756
2020
Q4
$333K Buy
+3,600
New +$321K 0.02% 817

Other funds holding DXCM

Point72 Hong Kong's DXCM Position: Q3 2025 in Review

Point72 Hong Kong opened a new position in DexCom (DXCM) in Q3 2025: 30,023 shares worth $2.02M. The stake represents 0.09% of the portfolio and ranks #155 among its holdings. This is a return to the name: Point72 Hong Kong previously reported a position in DXCM as recently as Q1 2025.

Point72 Hong Kong first reported a position in DXCM in Q1 2017 and has held it in 17 quarters since. The position peaked at $12.3M in Q4 2023. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • Point72 Hong Kong held 30,023 shares of DexCom worth $2.02M as of Q3 2025.
  • DexCom was a new Point72 Hong Kong position in Q3 2025.
  • DexCom made up 0.09% of Point72 Hong Kong's portfolio in Q3 2025, its #155 holding.
  • Point72 Hong Kong first reported a position in DexCom in Q1 2017 and has held it in 17 quarters since.
  • Point72 Hong Kong's DexCom position peaked at $12.3M in Q4 2023.
  • 911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Point72 Hong Kong's 13F filing for Q3 2025, filed 14 Nov 2025.